The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Open accessAbstract
Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit. However, many patients with cancer fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the underlying mechanism(s) is not well understood. Recent studies revealed that response to PD-1-PD-L1 blockade might correlate with PD-L1 expression levels in tumour cells. Hence, it is important to understand the mechanistic pathways that control PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1-PD-L1 blockade in patients with cancer. Here we show that PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases PD-L1 protein levels by impeding cyclin D-CDK4-mediated phosphorylation of speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the anaphase-promoting complex activator FZR1. Loss-of-function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumour-infiltrating lymphocytes in mouse tumours and in primary human prostate cancer specimens. Notably, combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and markedly improves overall survival rates in mouse tumour models. Our study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, several critical proteins including CMTM4, CMTM6, GSK3β, CSN5, CDK4, CDK6, and palmitoylated B3GNT3 have been shown to affect post-translational PD-L1 stability31–36.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the Cullin 3-SPOP E3-ligase complex can directly ubiquitinate PD-L1 in a cell-cycle dependent manner, leading to its degradation [15].”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“First, as previously described [15], perturbation of the CUL3-SPOP complex interferes with the ubiquitination of PD-L1, directly enhancing its stability and protein expression level.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“we verified that perturbation of BHLH transcription factor MYC [12] and the ubiquitin ligase CUL3 [15] both increased PD-L1 protein levels, consistent with previous reports.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
In the citing paper
“CDK4 was shown to have kinase activity towards SPOP, a cullin 3 E3 ubiquitin ligase adaptor protein that can interact with PD-L1 (Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Treatment with palbociclib inhibits SPOP phosphorylation, promoting its degradation and blocking PD-L1 proteasome mediated degradation.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Combining palbociclib with a PD-1 blockade enhanced tumor regression and improved overall survival in mouse xenograft models of colon adenocarcinoma (Deng et al., 2017; Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A. A., Ahn, J., Akbani, R., Ally, A., Amin, S. B., Andry, C., Annala, M., Aprikian, A. G., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,126
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationTaxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,931
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P. P., White, T. A., Stojanov, P., Allen, E. M. V., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,550
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Liang, J., Sun, G., Pan, X., Zhang, M., Shen, P., Zhu, S., Zhao, J., Zheng, L., Zhao, J., Chen, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22735554
Гречухина, К. С., Filonenko, D., Сухова, М. В., & Zhukova, L. (2024) · Journal of Modern Oncology · doi:10.26442/18151434.2024.2.202748
Wei, X., Zhang, Y., Wang, Y., Chen, X., Dong, J., ZHANG, W., Pang, Q., Wang, P., & Zhang, T. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4883523
Expression and prognostic value of cell‐cycle‐associated genes in lung squamous cell carcinoma
Xu, X., Jin, K., Xu, X., Yang, Y., & Zhou, B. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3735
Guo, Y. (2024) · American Journal of Cancer Research · doi:10.62347/timd7591
Yuan, K., Chen, W., Wang, X., & Yang, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00022-4
Targeting CDK4 and CDK6 in hormone-dependent cancers
Bobbitt, J. R., & Keri, R. A. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.10.006
The Potential Impact of BI-D1870, a Ribosomal S6 Kinase Inhibitor, on PD-L1 Expression Control
Nihira, N. T., Takeyama, T., Wu, W., & Ohta, T. (2024) · Journal of St Marianna University · doi:10.17264/stmarieng.15.45
Self-citationDual Inhibitors of CDK4 /6 for Treating Cancer
Toogood, P. L. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch22
Immune Gene Signature as a Predictor of CDK4/6 Inhibitor Response in HR+/HER2– Breast CancerPreprint
Felip, E., García-Vidal, E., Heras, S. C. L., Bernat‐Peguera, A., Cirauqui, B., Bergamino, M. A., Quiroga, V., Teruel, I., Ferrando‐Díez, A., Pous, A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6129690/v1
Ma, J., Wang, Y., Wu, Z., Zhou, L., Lin, Y., Xu, S., Zhang, J., Lu, J., & Yin, W. (2025) · iScience · doi:10.1016/j.isci.2025.112620
Self-citationCurrent progress in targeting mitotic kinases in PDAC
Barlow, T. M. A., Rooman, I., & Ballet, S. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00162e
Kolyadina, I. V. (2025) · Tumors of female reproductive system · doi:10.17650/1994-4098-2025-21-2-47-59
Optochemical control of G1 cell cycle by regulating CDK4/6 degradation
Wang, T., Zhang, Y., Liu, Y., Wang, L., Liu, L., & Wang, W. (2025) · iScience · doi:10.1016/j.isci.2025.113304
Circ_0074158 and QKI6: A regulatory axis for PD-L1 ubiquitination and immune evasion in NSCLC
Zhang, H., Liu, X., Lei, J., Tian, F., Liu, X., Lv, F., Kang, S., Lan, K., Wang, J., Yan, X., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04152-7
Identifying potential therapeutic targets for prostate cancer with mediating role in tumor immunity
Wu, Z., Li, S., Li, Y., Wang, Z., & Wang, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-02985-3 · Cited by 1
Zhang, Z., Li, Y., Leturcq, M., Abula, Y., Wu, X., & Kimata, Y. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.13.675969
Xie, G., Gao, L., Tian, L., Li, X., Zheng, T., Yu, X., Jiang, H., & Chen, Z. (2025) · STAR Protocols · doi:10.1016/j.xpro.2025.104150
Hu, S.-W., Yeh, M., He, Y., Wei, Y.-L., Cheng, F., Yeh, Y., Huynh, T. K., Liu, P.-T., Hu, D.-W., Chang, T.-H., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102429 · Cited by 1
Wan, Y., Wang, J., O’Connor, T. N., Kumarasamy, V. M., Sanidas, I., Abrams, S. I., Witkiewicz, A. K., & Knudsen, E. S. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00845-5
Sun, Y., Wang, J., Ma, Y., Li, J., Sun, X., Zhao, X., Shi, X., Hu, Y., Qu, F., & Zhang, X. (2021) · Figshare · doi:10.6084/m9.figshare.16703293
Self-citationZhang, Z., Wang, G., Zhong, K., Chen, Y., Yang, N., Lu, Q., Yuan, B., Wang, Z., Li, H., Guo, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561162
Huang, Y., Liu, H., Liu, B., Chen, X., Li, D., Xue, J., Li, N., Zhu, L., Yang, L., Xiao, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25195118
Self-citationHuang, Y., Liu, H., Liu, B., Chen, X., Li, D., Xue, J., Li, N., Zhu, L., Yang, L., Xiao, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26678840
Self-citationHuang, Y., Liu, H., Liu, B., Chen, X., Li, D., Xue, J., Li, N., Zhu, L., Yang, L., Xiao, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25194768
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561060
Sun, Y., Wang, J., Ma, Y., Li, J., Sun, X., Zhao, X., Shi, X., Hu, Y., Qu, F., & Zhang, X. (2021) · Figshare · doi:10.6084/m9.figshare.16703278
Self-citationSun, Y., Wang, J., Ma, Y., Li, J., Sun, X., Zhao, X., Shi, X., Hu, Y., Qu, F., & Zhang, X. (2021) · Figshare · doi:10.6084/m9.figshare.16703287
Self-citationLiang, J., Sun, G., Pan, X., Zhang, M., Shen, P., Zhu, S., Zhao, J., Zheng, L., Zhao, J., Chen, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22735557
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561033
Li, Z., Xue, H., Li, J., Zheng, Z., Liu, Z., Dong, X., Wang, H., Chen, J., & 徐双兵 (2024) · Figshare · doi:10.6084/m9.figshare.25464949
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561042
Han, S., Zhen, W., Guo, T., Zou, J., & Li, F. (2020) · Figshare · doi:10.6084/m9.figshare.13100785
Sun, Y., Wang, J., Ma, Y., Li, J., Sun, X., Zhao, X., Shi, X., Hu, Y., Qu, F., & Zhang, X. (2021) · Figshare · doi:10.6084/m9.figshare.16703269
Self-citationSun, Y., Wang, J., Ma, Y., Li, J., Sun, X., Zhao, X., Shi, X., Hu, Y., Qu, F., & Zhang, X. (2021) · Figshare · doi:10.6084/m9.figshare.16703272
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561039
Sun, Y., Wang, J., Ma, Y., Li, J., Sun, X., Zhao, X., Shi, X., Hu, Y., Qu, F., & Zhang, X. (2021) · Figshare · doi:10.6084/m9.figshare.16703281
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561048
Huang, Y., Chen, D., Bai, Y., Zhang, Y., Zheng, Z., Fu, Q., Yi, B., Jiang, Y., Zhang, Z., & Zhu, J. (2024) · Figshare · doi:10.6084/m9.figshare.26705250
Self-citationHuang, Y., Chen, D., Bai, Y., Zhang, Y., Zheng, Z., Fu, Q., Yi, B., Jiang, Y., Zhang, Z., & Zhu, J. (2024) · Figshare · doi:10.6084/m9.figshare.25591495
Self-citationAdditional file 1 of Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Figshare · doi:10.6084/m9.figshare.14737077
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561045
Sun, Y., Wang, J., Ma, Y., Li, J., Sun, X., Zhao, X., Shi, X., Hu, Y., Qu, F., & Zhang, X. (2021) · Figshare · doi:10.6084/m9.figshare.16703290
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561054
Huang, Y., Chen, D., Bai, Y., Zhang, Y., Zheng, Z., Fu, Q., Yi, B., Jiang, Y., Zhang, Z., & Zhu, J. (2024) · Figshare · doi:10.6084/m9.figshare.25591342
Self-citationZhu, J., Huang, R., Yang, R., Xiao, Y., Yan, J., Zheng, C., Xiao, W., Huang, C., & Wang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16800398
Sun, Y., Wang, J., Ma, Y., Li, J., Sun, X., Zhao, X., Shi, X., Hu, Y., Qu, F., & Zhang, X. (2021) · Figshare · doi:10.6084/m9.figshare.16703275
Self-citationKim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561051
Huang, Y., Chen, D., Bai, Y., Zhang, Y., Zheng, Z., Fu, Q., Yi, B., Jiang, Y., Zhang, Z., & Zhu, J. (2024) · Figshare · doi:10.6084/m9.figshare.26705247
Self-citationLiang, J., Sun, G., Pan, X., Zhang, M., Shen, P., Zhu, S., Zhao, J., Zheng, L., Zhao, J., Chen, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22735551
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561057
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561036
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S.-G., Kim, G. M., Kim, T. Y., Ryu, W.-J., Kim, J. Y., Park, H. S., Park, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26561063
Sun, Y., Wang, J., Ma, Y., Li, J., Sun, X., Zhao, X., Shi, X., Hu, Y., Qu, F., & Zhang, X. (2021) · Figshare · doi:10.6084/m9.figshare.16703284
Self-citationXu, Q., Li, C., Zhao, A., Xie, J., Lu, M., Huang, M., Huang, W., & Huang, R. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153186
Wang, Z., & Wu, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1724319
li, Y., Zeng, J., Gong, X., Li, W., Liu, J., Li, D., Zhong, Y., Deng, J., Deng, J., Feng, H., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1542784
FBXO9 promotes anti-tumor immunity via degradation of PD-L1 in pancreatic cancer
Cao, T., Zheng, R., Wang, Y., Yu, Z., Huang, H., Chen, Y., Pan, X., Gao, Y., Song, W., Xia, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1726825
Ubiquitination and Degradation Mechanisms of Immune Checkpoint Genes in Tumors
窦, 家. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161264
Kolyadina, I. V., Khokhlova, S. V., Bikeev, Y. V., Зайцев, Н. А., & Poddubnaya, I. V. (2026) · Tumors of female reproductive system · doi:10.17650/1994-4098-2025-21-4-71-84
Sato, C., Taylor, M. T., & Martinez, D. (2023) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/hldmpyjetk
Rodriguez, J. A., & Diaz, P. I. (2023) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/elsecc2ogz
Sears-Smith, M., Matusz‐Fisher, A., Symanowski, J. T., & Tan, A. R. (2026) · Future Oncology · doi:10.1080/14796694.2026.2639737
Li, B., Wei, P., Xie, B., Zhong, X., Wang, X., Lou, X., Zhang, T., & Dong, C. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218464 · Cited by 1
Qiao, J., Li, X., Qin, Z., Zhao, P., Zhou, H., Qiu, L., Yuan, Y., & Zhong, L. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1779213
Crizotinib-Induced Immunogenic Cell Death in Non-Small Cell Lung Cancer
Liu, P. (2018) · theses.fr (ABES) · doi:10.70675/ed550df1z9febz41d6z9846z294a6695b865
Immune Checkpoints in Peritoneal Carcinomatosis : HLA-G, PD-L1 & the Impact of Cancer Therapies
Ullah, M. (2019) · theses.fr (ABES) · doi:10.70675/6b7b16b5z18e9z4f6cz8371z93d206b34a18
Rôle de Programmed cell Death-Ligand 1 dans la progression du carcinome hépatocellulaire
Rousseau, B. (2021) · theses.fr (ABES) · doi:10.70675/dd181429zd664z4681zbe04z06271b5e1f39
Ciblage thérapeutique de la protéine CDK6 dans les leucémies aiguës myéloïdes
Brault, L. M. (2022) · theses.fr (ABES) · doi:10.70675/26bca708z5a9az4d80z85bfz9159b330b1e8
Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo
Drabison, T., Ahmed, E. H., Colasanti, N., Weber, R. H., Sparreboom, A., & Eisenmann, E. D. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04877-x
Mapping the immune microenvironment of non-small cell lung cancer
Ge, X., Cai, M., Nie, J., Wang, L., Li, Y., Hu, Y., Meng, J., Liu, H., Geng, L., 花宝金, et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105335
Lu, Y., Qian, Y., Ma, Y., Shao, X., & Xie, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1775447
Post-translational modifications of PD-L1 and interactions in breast cancer progression
Qi, J., Sun, A., & Dai, H. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102192
Wang, Y., Reshetnikova, E., Katuwal, N. B., Bharti, V., Pereira, M. S., Oppong, B. A., Lee, D. A., Mittra, A., Freud, A. G., & Vilgelm, A. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.19.719504
Bi, L., Xie, Q., Zhang, J.-T., Cai, S., Wang, X.-M., & Li, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1783525
Self-citationLee, P.-Y., Lee, P. Y., Tu, H., Liao, T.-L., Chung, Y.-H., Chiang, I., & Hsu, F. (2026) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.04.084
Wang, Z., Song, P., Wu, X., Wang, L., Xie, W., Feng, P., Cheng, C., & Guo, J. (2026) · Advanced Science · doi:10.1002/advs.75693
Self-citationCui, J., Zhang, Y., Wu, Y., Zhang, G., Lan, J., & Wang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845921
Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation
Zhang, Q., Yuan, C., Zhu, L., Zheng, S., Xu, Y., 车炫霖, Xiao, S., Liu, J., Hong, L., Li, H., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02694-7
miR-133b induces antitumor immunity in cervical cancer through modulating CMTM6/PD-L1 axis
Tan, W.-M., Wang, J.-Q., Li, L., Liu, X.-J., Wang, H., & Zeng, H. (2026) · Molecular Genetics and Genomics · doi:10.1007/s00438-026-02426-y
Self-citationKoukourakis, I. M., Platoni, K., Kouloulias, V., Yfanti, C., Arelaki, S., Kalaitzis, C., Zygogianni, A. G., Koukourakis, M. I., & Giatromanolaki, A. N. (2026) · Cancers · doi:10.3390/cancers18132149
Regulation of PD-1 and PD-L1 expression in tumor immune microenvironment
Liu, P., Han, G., Chen, Z., & Wu, J. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152522
Kuan, L., Jia, Z., 鲁海文, Wang, Q., Haihui, H., Yan, Z., Wang, Y., & Liu, X. (2026) · Discover Oncology · doi:10.1007/s12672-026-05544-6
Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination
Lin, X., Wang, Q., Xu, M., Yu, D., Hu, H., Zhang, Q. H., Yao, J., Xie, M., Xu, H., Zang, X., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102920
Post-translational modifications in glioma immune evasion and immunotherapy resistance
Wei, W., 轩玉琴, Cheng, L., & Dai, Q. (2026) · Discover Oncology · doi:10.1007/s12672-026-05592-y
Self-citationCheng, Y., Chen, Y., Wang, J., Shu, Z., Yang, Y., Wu, Y., Li, Z., & Zhang, Y. (2026) · Oncogene · doi:10.1038/s41388-026-03915-5
Ubiquitin-dependent control of PD-L1 nuclear translocation by DDB1 dictates anti-PD-1 response
Wang, Z., Shi, C., Cheng, G., Gao, Z., Wang, K., Zhao, Q., Lin, A., & Liu, Y. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.07.077
Chen, S., Yang, L., Liang, Z.-Q., Li, J., Li, S.-D., Deng, Y.-L., Chen, G., Ling, J.-W., Zhou, S.-S., Chen, G., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72028
Chen, C., Shi, J., Lei, Y., Wang, Q., Cao, P., Hou, D., Huang, M., Wang, R., Mu, Q., Lv, T., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76158-3
Self-citationImmune Checkpoint Inhibitors: Mechanisms and Emerging Challenges
Gill, G. S., Karmakar, S., & Goswami, S. (2026) · Springer eBooks · doi:10.1007/978-981-92-0477-9_22
Ku, Y., Zheng, Y., Ding, Y., Zhang, P., Wu, X., & Chen, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167119
Tang, T., Yang, W., Lu, M., Peng, D., Li, S., Cui, S., Ye, S., Liu, J., Wang, Y., 吴存瑾, et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01845-z
Self-citationZheng, C., Pan, Y., Zheng, D., & Pan, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1934879
CDK4/6 inhibitors: drug discovery, development, and classification
Gupta, S., Chahat, Kumar, B., Kumar, M., Wahajuddin, M., & Joshi, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44611-5.00004-3
Ren, H., Li, X., Jiang, Z., Bai, Y., & Ai, J. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189692
Metadata
- Authors
- Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., Guo, J., Huang, Y.-H., Fan, C., Ren, S., Sun, Y., Freeman, G. J., Sicinski, P., & Wei, W.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Second Military Medical University (CN)
- Corresponding author
- Freeman, Gordon J.
- Wei, Wenyi
- ORCID
- Venue
- Nature
- Published
- 2017-11-16
- Volume
- 553
- Issue
- 7686
- Pages
- 91-95
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5754234
- OpenAlex
- W2769376007
- Cited by
- 1,013
- References
- 43
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 138 · 2023: 140 · 2022: 134 · 2021: 157 · 2020: 118 · 2019: 78 · 2018: 43
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-07-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, R01CA229307, R01CA200573, K99CA212292, R01CA177910, P50CA101942, R01CA132740, R01CA202634, P01CA080111, R01CA200651, R01CA083688)
- National Institute of General Medical Sciences (R01GM094777, R01GM089763)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-L1, anti-PD-1 therapy, CDK4/6 inhibitors, FZR1, proteasomal degradation, polyubiquitination, tumor immune evasion, immune checkpoint blockade, combination immunotherapy, tumor immune microenvironment
- MeSH terms
- Animals, Cell Cycle, Cell Line, Female, Humans, Immunologic Surveillance, Male, Neoplasms, Nuclear Proteins, Phosphorylation, Prostatic Neoplasms, Repressor Proteins, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Cullin Proteins, Proteasome Endopeptidase Complex, 14-3-3 Proteins, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Protein Stability, Cyclin D, Proteolysis, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Cdh1 Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
